AtaiBeckley (STU:B72) Days Payable: 0.00 (As of Mar. 2026)

What is AtaiBeckley Days Payable?

AtaiBeckley STU:B72 51 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates STU:B72 with a GF Score™ of 51/100 and a GF Value™ of €6.32. The stock has 4 warning signs investors should review. Among 708 Biotechnology companies, AtaiBeckley ranks worse than 141242.8% on this metric.

AtaiBeckley's average Accounts Payable for the three months ended in Mar. 2026 was €6.76 Mil. AtaiBeckley's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for AtaiBeckley's Days Payable or its related term are showing as below:

STU:B72's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

AtaiBeckley's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

AtaiBeckley Days Payable Related Terms

AtaiBeckley Days Payable Historical Data

* Premium members only.

The historical data trend for AtaiBeckley's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtaiBeckley Days Payable Chart

AtaiBeckley Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

AtaiBeckley Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

STU:B72 vs GLUE, NUVB, BHVN: Days Payable Comparison

For the Biotechnology subindustry, AtaiBeckley's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AtaiBeckley Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AtaiBeckley's Days Payable distribution charts can be found below:

* The bar in red indicates where AtaiBeckley's Days Payable falls into.

Save Embed

51GF Score

AtaiBeckley Inc STU:B72

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

AtaiBeckley Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

AtaiBeckley's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (2.498	+	4.19)	/	2 )	/	0	*	365
=	3.344					/	0	*	365
=	N/A

AtaiBeckley's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (4.19	+	9.329)	/	2 )	/	0	*	365 / 4
=	6.7595					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

AtaiBeckley (STU:B72) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AtaiBeckley and its competitors. According to the industry distribution chart, AtaiBeckley ranks #999999 out of 708 companies in the Biotechnology industry.

Is AtaiBeckley's Days Payable too high?

AtaiBeckley's current Days Payable is 0.00. Based on the distribution chart, AtaiBeckley ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AtaiBeckley has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.

How does AtaiBeckley's Days Payable compare to GLUE and NUVB?

According to the Biotechnology industry distribution chart, AtaiBeckley ranks #999999 out of 708 companies for Days Payable. This places AtaiBeckley in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AtaiBeckley and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtaiBeckley's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is AtaiBeckley stock overvalued right now?

AtaiBeckley (STU:B72) has a current Days Payable of 0.00. The stock's GF Value™ is €6.32, compared to a current price of €3.45 — trading 45.5% below its estimated fair value. The current Days Payable is 0.00. AtaiBeckley's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For AtaiBeckley (STU:B72), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtaiBeckley (STU:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €3.45 is trading 45.5% below its estimated GF Value™ of €6.32.

Key valuation signals for STU:B72:

Days Payable: 0.00
GF Value™: €6.32 vs. price of €3.45 (45.5% below fair value)
GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtaiBeckley Business Description

Industry Healthcare Biotechnology

Comparable Companies GLUE NUVB BHVN GENB TSHA GHRS PVLA VCEL ANAB VIR VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ATAI:USA B72:Germany

Address 250 West 34th Street, New York, NY, USA, 10119

Website https://www.ataibeckley.com

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

51GF Score

Get the complete analysis for STU:B72

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.45

Price

€6.32

GF Value

View STU:B72 Analysis

See Days Payable data for all stocks →